These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28361437)

  • 1. Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis.
    Vállez García D; Doorduin J; de Paula Faria D; Dierckx RAJO; de Vries EFJ
    J Neuroimmune Pharmacol; 2017 Sep; 12(3):521-530. PubMed ID: 28361437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
    Airas L; Dickens AM; Elo P; Marjamäki P; Johansson J; Eskola O; Jones PA; Trigg W; Solin O; Haaparanta-Solin M; Anthony DC; Rinne J
    J Nucl Med; 2015 Feb; 56(2):305-10. PubMed ID: 25572093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model.
    de Paula Faria D; Vlaming ML; Copray SC; Tielen F; Anthonijsz HJ; Sijbesma JW; Buchpiguel CA; Dierckx RA; van der Hoorn JW; de Vries EF
    J Nucl Med; 2014 Aug; 55(8):1330-5. PubMed ID: 24914056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
    Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
    J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
    J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod effects in neuroinflammation: Regulation of astroglial glutamate transporters?
    Lee DH; Seubert S; Huhn K; Brecht L; Rötger C; Waschbisch A; Schlachetzki J; Klausmeyer A; Melms A; Wiese S; Winkler J; Linker RA
    PLoS One; 2017; 12(3):e0171552. PubMed ID: 28273090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
    Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
    Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection.
    Ambrosius B; Pitarokoili K; Schrewe L; Pedreiturria X; Motte J; Gold R
    J Neuroinflammation; 2017 Apr; 14(1):92. PubMed ID: 28446186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 (fingolimod) regulates key target genes essential for inflammation in microglial cells as defined by high-resolution mRNA sequencing.
    Das A; Arifuzzaman S; Kim SH; Lee YS; Jung KH; Chai YG
    Neuropharmacology; 2017 Jun; 119():1-14. PubMed ID: 28373076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
    de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ
    Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple pathological mechanisms contribute to hippocampal damage in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Kyran EL; Robinson C; Kocovski P; Li Z; Dang PT; Hale MW; Orian JM
    Neuroreport; 2018 Jan; 29(1):19-24. PubMed ID: 29194293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
    Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
    Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats.
    Milicevic I; Pekovic S; Subasic S; Mostarica-Stojkovic M; Stosic-Grujicic S; Medic-Mijacevic L; Pejanovic V; Rakic L; Stojiljkovic M
    J Neurosci Res; 2003 Apr; 72(2):268-78. PubMed ID: 12672002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis.
    Buonvicino D; Pratesi S; Ranieri G; Pistolesi A; Guasti D; Chiarugi A
    Neurobiol Dis; 2024 Feb; 191():106387. PubMed ID: 38142841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
    Zhang J; Zhang ZG; Li Y; Ding X; Shang X; Lu M; Elias SB; Chopp M
    Neurobiol Dis; 2015 Apr; 76():57-66. PubMed ID: 25680941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of system xc- as a novel approach to monitor multiple sclerosis.
    Martín A; Vázquez-Villoldo N; Gómez-Vallejo V; Padro D; Soria FN; Szczupak B; Plaza-García S; Arrieta A; Reese T; Llop J; Domercq M; Matute C
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1124-38. PubMed ID: 26659901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
    Samuvel DJ; Saxena N; Dhindsa JS; Singh AK; Gill GS; Grobelny DW; Singh I
    PLoS One; 2015; 10(10):e0141781. PubMed ID: 26513477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Zinger A; Latham SL; Combes V; Byrne S; Barnett MH; Hawke S; Grau GE
    Mult Scler; 2016 Dec; 22(14):1883-1887. PubMed ID: 26931477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.